- Conference: AIChE Annual Meeting
- Year: 2017
- Proceeding: 2017 Annual Meeting
- Group: Topical Conference: Innovations of Green Process Engineering for Sustainable Energy and Environment
- Time: Tuesday, October 31, 2017 - 2:20pm-2:42pm
To encourage the adoption of innovative approaches in pharmaceutical manufacturing and to prepare for reviews and inspections involving technology for which there is little experience, the Agency established the Emerging Technology Program. This program features a cross-functional Emerging Technology Team (ETT) which works directly with industry to identify and resolve potential scientific and policy issues that may impact technologies new to the pharmaceutical industry. In a relatively short period of time, the Emerging Technology Program has facilitated the approvals of the first 3D-printed drug product, the first drug product made via continuous manufacturing, and the first switch to a continuous manufacturing process for an approved drug product.
Advancements in regulatory science are essential to FDAâs mission and enable the ETT to issue clear recommendations to sponsors about the risks and benefits of products that involve new technologies. FDAâs research program aims to address any knowledge and experience gaps to support these needed improvements. The knowledge gained from the internal and sponsored research will inform policy, review, and inspection activities, ensuring that FDA regulatory policies reflect state-of-the-art manufacturing science.
In this talk, FDAâs emerging technology program is described including a summary of industry interactions and observed trends. FDAâs manufacturing science research programs are highlighted e.g. continuous manufacturing, 3D printing, and process modeling to demonstrate how advances in regulatory science support the emerging technology program.